Advertisement

Topics

COPD and Asthma Drugs Market by Disease COPD and Asthma by Medication Class Combination Drugs, Inhaled Corticosteroids ICS, Short Acting Beta Agonists SABA, Long Acting Beta Agonists LABA, Leukotriene Antagonists LTA, Anticholinergics and Others and by Ge

10:44 EDT 1 Aug 2017 | BioPortfolio Reports

Asthma is a chronic respiratory disease blocking the airways of the lungs because of the inflammation, mucus production, tighten of muscles. The general symptoms are coughing, wheezing, shortness of breath and/or chest tightness and majorly these symptoms are closely related to the physical activity. There are different types of asthma, exerciseinduced bronchoconstrictionEIB, allergic asthma, occupational asthma, childhood asthma. Chronic Obstructive Pulmonary Disease COPD is also respiratory disease which causes obstructions and difficulty in breathing, the primary cause of COPD is tobacco smoking and chemical flumes, dust, air pollution are minor causes of the disease. Major symptoms are long lasting cough, mucus that comes out along with cough, shortness of breath.nnThe world COPD and asthma drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Increase in prevalence of asthma and COPD, increase in world ageing population, technological advancement in the treatment of asthma and COPD, growth in initiatives implemented by the government and nongovernment associations for rise in health awareness play a pivotal role in the growth of the global COPD and asthma drug market. Stringent government regulatory requirement for the approval of COPD and asthma drug, patent expiry of branded hamper the market growth.nnThe world asthma and COPD drugs market is segmented based on disease and medication class and geography. On the basis of disease, the market is segmented into COPD and asthma. Based on medication class, the world asthma and COPD drug market is segmented into combination products, short acting beta agonists SABA, long acting beta agonists LABA, inhaled corticosteroids ICS, leukotriene antagonists LTA, anticholinergics and others. And geographically, the market is segmented into North America, Europe, AsiaPacific, and LAMEA.nnKey benefitsnnnnThe study provides an indepth analysis of the asthma and COPD drug market with current trends and future estimations to elucidate the imminent investment pockets in the market.nnThe report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.nnExtensive analysis of the asthma and COPD drug market, by medication class, helps in the treatment of asthma and COPD diseases.nnCompetitive intelligence highlights the business practices followed by leading market players across various geographic regions.nnKey market players within the asthma and COPD drug market are profiled in this report and their strategies are analyzed thoroughly, which predicts the competitive outlook of global asthma and COPD drug market.nnKey market segmentsnnThe world COPD and asthma drug market is segmented by medication class, disease and geography.nnnMARKET BY DISEASESnnnnCOPDnnAsthmannnMARKET BY MEDICATION CLASSnnnnCombination ProductsnnnnnnSeretide/AdvairnnnSymbicortnnnRelvar/Breo ElliptannnFlutiformnnnDulerannnOthersnnnnnnLeukotriene Antagonists LTAnnnnnSingulairnnnOthersnnnnnnInhaled Corticosteroids ICSnnnnnQvarnnnPulmicortnnnAerospannnnFloventnnnOthersnnnnnnAnticholinergicsnnnnnSpirivannnOthersnnnnnnShort Acting Beta AgonistsSABAnnnnnProAirnnnVentolinnnnOthersnnnnnnLong Acting Beta Agonists LABAnnOthersnnnMARKET BY GEOGRAPHYnnnnNorth AmericannnnnnU.S.nnnCanadannnMexiconnnnnnEuropennnnnU.K.nnnFrancennnGermanynnnItalynnnRest of EuropennnAsiaPacificnnnJapannnnChinannnIndiannnnnnRest of AsiaPacificnnnnnLAMEAnnnLatin AmericannnMiddle EastnnnAfricannnnnnnKEY PLAYERSnnnnGlaxoSmithKline GSKnnNovartis AG.nnMerck amp; Co.nnAbbott Laboratories.nnBoehringer Ingelheim.nnAstraZeneca.nnRoche Holding AGnnTeva Pharmaceutical Industries.nnVectura GroupnnPfizernnnOther players in the value chain include profiles not included in the reportnnnnMylannnAerovance Inc.nnAlkermes Inc.nnAlmirall SAnnGenentech Inc.nnSepracor, Inc.nnSkyepharma plcn

Original Article: COPD and Asthma Drugs Market by Disease COPD and Asthma by Medication Class Combination Drugs, Inhaled Corticosteroids ICS, Short Acting Beta Agonists SABA, Long Acting Beta Agonists LABA, Leukotriene Antagonists LTA, Anticholinergics and Others and by Ge

NEXT ARTICLE

More From BioPortfolio on "COPD and Asthma Drugs Market by Disease COPD and Asthma by Medication Class Combination Drugs, Inhaled Corticosteroids ICS, Short Acting Beta Agonists SABA, Long Acting Beta Agonists LABA, Leukotriene Antagonists LTA, Anticholinergics and Others and by Ge"

Quick Search
Advertisement
 

Relevant Topics

Asthma
Asthma is caused by inflammation of small tubes, called bronchi, which carry air in and out of the lungs. If you have asthma, the bronchi will be inflamed and more sensitive than normal.  When you come into contact with something that irritates your...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...